On Setting Expectations for a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine

Clin Infect Dis. 2021 Feb 1;72(3):513-514. doi: 10.1093/cid/ciaa726.

Abstract

The global coronavirus pandemic is unlike any other since 1918. A century of dramatic medical advances has produced a public expectation that the medical field will rapidly provide solutions to restore normalcy. In less than 6 months, since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified, the massive international effort to develop a SARS-CoV-2 vaccine has generated more than 140 vaccines in different stages of development, with 9 already recruiting into clinical trials posted on ClinicalTrials.gov. The long-term strategy to handle coronavirus disease 2019 (COVID-19) will almost certainly rely on vaccines. But what type of protection can we realistically expect to achieve from vaccines and when?

Keywords: COVID-19; SARS-CoV-2; T cells; vaccine.

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • Motivation
  • SARS-CoV-2
  • Vaccines*
  • Viral Vaccines*

Substances

  • COVID-19 Vaccines
  • Vaccines
  • Viral Vaccines